MAT

Virtual opioid agonist treatment: Alberta’s virtual opioid dependency program and outcomes

Citation
Day, N., Wass, M. & Smith, K. Virtual opioid agonist treatment: Alberta’s virtual opioid dependency program and outcomes. Addict Sci Clin Pract 17, 40 (2022). https://doi.org/10.1186/s13722-022-00323-4
Publication Date

Abstract

Background

Virtually delivered healthcare (telehealth, telemedicine) has the potential to reduce gaps in access to opioid agonist therapy (OAT). Barriers to accessing OAT such as lack of transportation, in-person induction requirements, employment demands and limited childcare options reduce treatment opportunities for clients. A completely virtual model of care has been developed in Alberta, Canada.

The influence of poly-drug use patterns on the association between opioid agonist treatment engagement and injecting initiation assistance

Citation
Meyers-Pantele, S.A., Mittal, M.L., Jain, S. et al. The influence of poly-drug use patterns on the association between opioid agonist treatment engagement and injecting initiation assistance. Subst Abuse Treat Prev Policy 17, 39 (2022). https://doi.org/10.1186/s13011-022-00470-6
Publication Date

Abstract

Background

Evidence suggests people who inject drugs (PWID) prescribed opioid agonist treatment (OAT) are less likely to provide injection drug use (IDU) initiation assistance. We investigated the association between OAT engagement and providing IDU initiation assistance across poly-drug use practices in Vancouver, Canada.

The Intersection of DEA, Opioids, and MAT

Online,

Wednesday, April 27, 2022 @ 3:00-4:00pm ET (2CT/1MT/12PT)

Description

As a result of the opioid crisis, more and more primary care providers are being asked to treat those suffering from opioid use disorder (OUD) through the use of medication assisted treatment (MAT).

The prevalence and pattern of cannabis use among patients attending a methadone treatment clinic in Nairobi, Kenya

Citation
Ngarachu, E.W., Kiburi, S.K., Owiti, F.R. et al. The prevalence and pattern of cannabis use among patients attending a methadone treatment clinic in Nairobi, Kenya. Subst Abuse Treat Prev Policy 17, 12 (2022). https://doi.org/10.1186/s13011-022-00437-7
Publication Date

Abstract

Background

Cannabis use during methadone treatment may negatively impact treatment outcomes. The aim of this study was to determine the prevalence and pattern of cannabis use among patients attending a methadone treatment clinic in Nairobi, Kenya.

Geographic Proximity to Buprenorphine Treatment Providers in the U.S.

Citation
Langabeer, J., Stotts, A. L., Cortez, A., Tortolero, G., & Champagne-Langabeer, T. (2020). Geographic proximity to buprenorphine treatment providers in the US. Drug and alcohol dependence, 108131.

Abstract

Objective

To combat the growing opioid epidemic, people who use drugs need access to medications for opioid use disorder (MOUD) as part of comprehensive treatment. Despite progress, treatment gaps remain. Our objective was to use a geospatial buffering model to estimate treatment access for buprenorphine providers nationally.

 

Drug Use and COVID-19 in Prisons: First Clinic Dedicated to the Treatment of People Living in Prisons with Opioid Use Disorders in Kenya

In 2018, Mombasa planned to set up a methadone programme for heroin injecting drug users living in prisons. As a follow up, UNODC worked together with the County of Mombasa and the Kenya Prison Service in 2019, to support and expand Medically Assisted Therapy (MAT) service provision to the prison population. Understanding that people in prison settings who use MAT services in the public-dedicated clinic could be unnecessarily put at risk of infection, and in

Cognitive Outcomes of Young Children After Prenatal Exposure to Medications for Opioid Use Disorder: A Systematic Review and Meta-Analysis

Citation
Nelson LF, Yocum VK, Patel KD, Qeadan F, Hsi A, Weitzen S. Cognitive Outcomes of Young Children After Prenatal Exposure to Medications for Opioid Use Disorder: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(3):e201195. doi:10.1001/jamanetworkopen.2020.1195
Publication Date

Abstract

Importance: The number of children with prenatal opioid exposure to medication for addiction treatment (MAT) with methadone and buprenorphine for maternal opioid use disorder is increasing, but the associations of this exposure with cognitive outcomes are not well understood.